OPS-2071

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Beijing Research Institute

Conditions

Crohn's DiseaseIrritable Bowel Syndrome of Diarrhea Type (IBS-D)

Phase 2

Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation

TerminatedNCT03850509

Otsuka Pharmaceutical Development & Commercialization, Inc.Crohn's Disease

Start: 2020-02-25End: 2020-05-22Updated: 2021-06-15

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

CompletedNCT05923892

Otsuka Beijing Research InstituteIrritable Bowel Syndrome of Diarrhea Type (IBS-D)

Start: 2023-08-02End: 2024-08-01Updated: 2025-04-03